The present paper describes a modified technique for heterotopic vascularized cardiac transplantation with updated aseptic technique, analgesia, and anesthesia.
The development of experimental models of cardiac transplantation in animals has contributed to many advances in the fields of immunology and solid organ transplantation. While the heterotopic vascularized murine cardiac transplantation model was initially utilized in studies of graft rejection using combinations of mismatched inbred mouse strains, access to genetically modified strains and therapeutic modalities can provide powerful new preclinical insights. Fundamentally, the surgical methodology for this technique has not changed since its development, especially with respect to important factors such as aseptic technique, anesthesia, and analgesia, which make material impacts on postsurgical morbidity and mortality. Additionally, improvements in perioperative management are expected to provide improvements in both animal welfare and experimental outcomes. This paper reports upon a protocol developed in collaboration with a subject matter expert in veterinary anesthesia and describes the surgical technique with an emphasis on perioperative management. Additionally, we discuss the implications of these refinements and provide details on troubleshooting critical surgical steps for this procedure.
We owe much of our understanding of immunology and transplantation to research based on experimental models of solid organ transplantation using animal subjects. Since the first description of vascularized cardiac transplantation in mammals1, such models have contributed to knowledge in wide-ranging domains, including the therapeutic application of hypothermia2, the benefits of using specialized sutures3, and techniques for total lung and heart homotransplantations4. The development of cardiac transplantation models in rats5,6 provided broader scope for immunological experimentation due to the availability of different breeding lines. The substantially wider range of available inbred and mutant mouse strains led Corry et al.7 to develop a technique of murine heterotopic cardiac transplantation due to the considerable advantages that this range brings to transplantation research. This model has been used widely and has contributed to a greater understanding of graft rejection8 and therapeutics9. Since its first description, however, the technique has remained largely unchanged other than some minor technical details such as adjustments to the position of anastomotic sites10,11.
Since the integration of the technique of Corry et al.7 into our experiments, we have identified areas of promise for improving the protocol, namely those of aseptic technique, anesthesia, and analgesia. Improvements in these areas were expected to offer a positive impact on experimental outcomes and improve animal welfare. This has previously been shown when aseptic technique is used in small animal surgeries as it aids in the reduction of postoperative infections12, which not only impacts morbidity and mortality but can also compromise experiments designed to assess the immune response following transplantation surgery. From an anesthesia and analgesic point of view, the use of a refined regimen helps to reduce the cost to animals and balance the ethical argument of this surgical model by mitigating the pain and suffering of experimental subjects. Further, appropriate anesthesia and analgesia limit the pain-associated stress response, improving the quality of postoperative recovery and, ultimately, increasing the surgical success rate13.
With the aim of improving both animal welfare and experimental outcomes, a protocol was developed with adjustments to bridge these gaps. This protocol has been adapted from that originally described by Corry et al.7 with consultation from a veterinary anesthetist and with due consideration for both the effects and duration of effects of the pharmacological interventions utilized in the anesthetic and analgesic regimen. The approach was based on the principles of balanced anesthesia and multimodal analgesia to ensure appropriate perioperative care14. In addition to the application of aseptic technique, the opioid buprenorphine and the local anesthetic bupivacaine were pre-emptively administered. General anesthesia was performed using the inhalant anesthetic agent isoflurane.
This research was performed in accordance with the Code of Practice for the Care and Use of Animals for Scientific Purposes15 and approved under Animal Ethics Protocols RA/3/100/1568 and AE173 (The University of Western Australia Animal Ethics Committee and The Harry Perkins Institute of Medical Research Animal Ethics Committee, respectively). See the Table of Materials for details regarding all materials, instruments, and animals used in this protocol.
1. Preparation of the animal for surgery
NOTE: Personnel are dedicated to either the role of performing surgery or monitoring anesthesia throughout the procedure.
2. Donor surgery
NOTE: See Supplemental Figure S1 for the key aspects of donor surgery.
3. Recipient surgery
4. Postoperative care
To determine the effectiveness of the surgical technique in promoting good outcomes of wound healing and mouse recovery, early experiments in the laboratory determined the survival characteristics of a range of heart grafts of variable immunogenicity to the recipient. These included congenic (n = 5) and syngeneic (n = 5) grafts, which share the same major histocompatibility complex (MHC) markers as the recipient, and major mismatch grafts (n = 9), in which the graft and the recipient have different MHC markers. We used direct palpation of the heterotopic abdominal heartbeat to assess ongoing graft function and viability, which serves as a proxy marker of rejection versus tolerance.
In both control groups, all grafts were viable at the experimental time endpoint of 100 days (mean undefined). The mismatched group had a mean survival time of 9 days. Figure 1 presents Kaplan-Meier survival curves demonstrating the stark contrast in graft survival between mismatched and control heart grafts16. These data are suggestive of the technique being sufficient to promote an appropriate healing response following the procedure. In the presence of pathological inflammation, however, in this case represented by graft rejection in the mismatch condition, tissue destruction leads to rapid loss of function.
Figure 1: The influence of mismatch on the survival of orthotopic heart transplants. Survival curves illustrating the full recovery and acceptance of syngeneic (n = 5) and congenic (n = 5) heterotopic murine heart transplants for at least 100 days post-surgery in contrast to the rapid rejection of major mismatched (n = 7) heterotopic murine heart transplants from as early as day 7 post surgery. These data were published in Prosser et al.16. Please click here to view a larger version of this figure.
Surgery Stage | Cold Ischemia time | Warm Ischemia time |
Donor | 13 – 15 min | |
Storage 4 °C | 20- 25 min | |
Recipient | 22 – 25 min |
Table 1: Range of warm and cold ischemia times for donor and recipient surgeries associated with the orthotopic heart transplant.
Supplemental Figure S1: Key aspects of donor surgery. (A) Isoflurane anesthesia; (B) heparin injection; (C) donor heart exposed; (D) flush of the heart with heparinized saline; (E) tying of the vessel; (F) donor heart for cold ischemia storage. Please click here to download this File.
Supplemental Figure S2: Key aspects of recipient surgery-preparation and cauterization of cut skin vessels. (A) Recipient surgical site preparation; (B) bupivacaine injection; (C) sterile surgical draping of the surgical site; (D) cauterization of the cut skin vessels. Please click here to download this File.
Supplemental Figure S3: Key aspects of recipient surgery-from repositioning of intestines to aortotomy. (A) Temporary repositioning of intestines; (B) inferior vena cava exposed and clamped; (C) placing the stay suture; (D) first phase: aortotomy. Please click here to download this File.
Supplemental Figure S4: Key aspects of recipient surgery-from venotomy to recovery. (A) Second phase: venotomy; (B) placing the gel foam; (C) reperfusion; (D) surgical closure; (E) recovery. Please click here to download this File.
The murine orthotopic heart transplant model is a robust preclinical model used primarily to investigate the effects of MHC mismatch on the level and nature of immunological rejection and, more recently, the effect of transplantation on the retention of graft tissue-resident immunity16. While initially closely following the Corry et al.7 protocol, we have refined the protocol to incorporate best-practice standards of aseptic technique, analgesia, and anesthesia. The updating of these new practices was achieved via additional training, the provision of sterile surgical gloves, gowns, and surgical drapes, the application of additional anesthesia, and the updating of the analgesia dosing. Such changes led to a small increase in surgical setup time and additional costs per surgery.
The use of animals to address important research concerns is permitted under a contract between researchers and an animal ethics committee (AEC) to maintain a social license to undertake such work. Decisions of an AEC are based on clear ethical guidelines15, with an overriding principle of balancing the costs to the animal against the benefits to society. The concept of the three Rs (reduction, replacement, and refinement) is vital in addressing how the costs of a project are mitigated.
Minimizing the harm to the animals involved by the adoption of species-appropriate, perioperative analgesia and anesthesia has an irreplaceable role in animal models of surgery and is an example of refinement. Additionally, care and techniques that reduce the risk of environmental and behavioral vectors of infection to the surgical recipient have positive implications for both reducing the harm to the animal in terms of morbidity and mortality and helping to minimize the financial costs associated with repeating failed surgeries. Although the cleanliness of the experimental animal "operating theater" does not closely approach that of a hospital equivalent, it should not be an afterthought in such work.
From a scientific perspective, postoperative infections necessarily influence the profile of inflammatory cytokines and immune cells, which are the typical readouts for experiments assessing transplant recovery or rejection. Maximal effort should, therefore, be made to control for postoperative infection, given the adverse impact this can have on the validity of the research. The focus on analgesia is important from an animal welfare point of view. Animal transplantation surgeries are major procedures, and great effort should be made in reducing unnecessary pain and suffering of the subjects. To return to the practical outcomes of this focus, an additional practical benefit of effective pain control is the reduced likelihood of animals being removed from the experimental protocol due to pain-associated signs of distress.
Since this procedure was first described, several authors have reported the troubleshooting of common problems that occur during the procedure10,11. The control of hemorrhage following the release of the clamps is well described and mirrors techniques used in human surgeries, namely the use of pressure to the site of hemorrhage, further suturing, and hemostatic agents. We have noticed that bleeding often occurs from one of two main sites: the anastomosis sites or damage to the myocardium. Approaches to halt bleeding from the heart have been reported by Niimi10, who controlled bleeding from the heart through ligation of the atrium. In our experience, the stemming of blood flow from the myocardium itself is exceptionally challenging due to its rich vascularization.
Due care must be exercised, therefore, to avoid such injury, which is caused most commonly by a miscontrolled forceps tip contacting the heart muscle during surgery. We, therefore, seek to only ever directly contact the heart muscle using moistened cotton-tipped applicators. To reduce direct contact in the manipulation of the heart, the free ends of the final silk ligation can be used to move the heart, such as when moving it from UWS to the thoracic cavity.
A second major challenge is the prevention of postoperative hind-limb paralysis, a complication that mandates euthanasia. Anecdotally, we have found that a warm ischemic time of >30 min is associated with a higher risk of this paralysis occurring. Our ischemic times are strictly monitored and recorded as an informal standard of performance. It should be noted, however, that ischemic time does not seem to reliably predict this complication. Niimi10, for example, a surgeon of substantial operative experience (over 3,000 surgeries), reported that ischemic times of up to 2 h are acceptable.
Perhaps even more startling than this, Abbott et al.5, who developed a similar technique in rats but used an end-to-end anastomotic setup in the abdomen (i.e., the IVC and abdominal aorta were ligated permanently), reported on two rats kept as long-term survivors lasting over 100 days without any apparent ill effects. These intergroup differences in outcomes are perhaps explained by subtly different techniques or, alternatively, by the genetic differences between different strains of mice. For example, we note that Ly5.1 mice are much more susceptible to this complication than BALB/c mice. To improve clarity on the effects of ischemic time on incidences of hind-limb paralysis, the effect of abdominal vessel occlusion time length could be investigated.
In summary, this described protocol provides straightforward refinements to established techniques using readily available drugs and materials. These refinements align the standard to which this surgical model is performed to that of clinical veterinary standards and benefit the animals and, ultimately, the research.
The authors have nothing to disclose.
The authors would like to acknowledge the superb efforts of the animal care staff of the University of Western Australia and of the Harry Perkins Institute of Medical Research, whose dedication and expertise contributed to the feasibility and success of these surgeries.
2030 Rycroft irrigating cannula 30 G | McFarlane | 56005HU | |
Braided surgical silk 7-0 | |||
Bulldog clamp curved – 35 mm | Roboz | RS-7441-5 | |
Bupivacaine 0.25% | |||
Buprenorphine | |||
Castroviejo needle holder catch curved - 145 mm | Haag-Streit | 11.62.15 | |
Chlorhexidine 5% solution | Ebos | JJ61371 | |
Cotton-tipped applicator – 7.5 cm | Dove | SN109510 | |
Ethanol 70% solution | Ebos | WH130192EE | |
Gauze 5 x 5 cm white | Aero | AGS50 | |
Gelfoam 80 mm x 125 mm | Pfizer | 7481D | |
Hair clipper | Wahl | 9860L | |
Heparin 1,000 IU in 1 mL | |||
Iris SuperCut scissors straight – 11.5 cm | Inka Surgical | 11550.11 | |
Isoflurane vaporiser | Darvall | 9176 | |
Micro bulldog clamp – 3.7 cm | Greman | 14119-G | |
Micro scissors curved 105 mm | |||
Micropore plain paper surgical tape – 2.5 cm wide | Ebos | 7810L | |
Microsurgical scissors – curved tip | |||
Monofilament polyprolene suture – 5/0 | Surgipro | P-205-X | |
Myweigh i101 Precision Scale 100 g x 0.005 g | Myweigh | Kit00053 | |
Needle – 30 G x 0.5 inch | BD | BD304000 | |
Needleholder 15 cm curved "super fine" | Surgical Specialists | ST-B-15-8.2 | |
Nylene 10/0 x 15 cm on 3.8 mm 3/8 circle round bodied taper (diam 0.07mm) CV300 | |||
Round body suture forceps curved 0.3 mm 120 mm | B. Braun | FD281R | |
Round body suture forceps straight 0.3 mm 120 mm | B. Braun | FD280R | |
Round handled vannas spring scissors-str/12.5 cm | 15400-12 | ||
Spring scissors-Cvd Sm blades | 15001-08 | ||
Stevens scissors blunt straight 110 mm | |||
Surgical backboard | Rigid laminated cardboard. 15 x 15 cm | ||
Surgical drapes | Cut into two sizes. 25 cm x 25 cm, and 25 cm x 40 cm | ||
Surgical microscope | |||
Syringe – 1 mL | BD | 592696 | |
Syringe – 3 mL | Leica | M651 | |
Toothed forceps | BD | 309657 | |
University of Wisconsin Solution | |||
Warming pad | Far infrared warming pad 20 x 25 cm | ||
Westcott spring scissors | |||
Yasargil clip applier bayonet | Aesculap | FE582K | |
Yasargil titanium clip perm 6.6 mm | Aesculap | A19FT222T | |
Mouse usage | |||
Strain/SEX/Weight | Donor | Recipent | |
BALB/c, female, 19-23 g | 7 | 21 | |
C57BL/6, female, 17-20 g | 7 | 0 | |
CD45.1 BALB/c, female, 17-21 g | 5 | 0 |